Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment

Therapeutic advance in progressive multiple sclerosis (MS) has been very slow. Based on the transformative role magnetic resonance imaging (MRI) contrast-enhancing lesions had on drug development for relapsing-remitting MS, we consider the lack of sensitive outcomes to be the greatest barrier for developing new treatments for progressive MS. The purpose of this study was to compare 58 prospecti...

متن کامل

Development, and evaluation of drug monitoring system for multiple sclerosis patients

Background and Aim: Taking a wide range of medications in Multiple sclerosis (MS) patients can lead to side effects and drug interactions. Therefore, the use of intelligent systems such as drug monitoring systems can help in the effective and timely treatment of MS disease. In this regard, the present study was conducted to design, development, and evaluation of the drug monitoring system for m...

متن کامل

P 57: The Effect of Biotin as a Therapeutic Agent for Progressive Multiple Sclerosis

Multiple sclerosis is an autoimmune disease caused by damage to the myelin of the nerve cells in the spinal cord and brain, MS was classified into 4 types including: Relasping/remitting (RR) primary/progressive (PP), secondary/progressive (SP), progressive/relapsing (PR). PR MS is one of the severe forms of MS that lead to inflammation associated physical, mental and vision dysfunction. Because...

متن کامل

Imaging outcome measures for progressive multiple sclerosis trials

Imaging markers that are reliable, reproducible and sensitive to neurodegenerative changes in progressive multiple sclerosis (MS) can enhance the development of new medications with a neuroprotective mode-of-action. Accordingly, in recent years, a considerable number of imaging biomarkers have been included in phase 2 and 3 clinical trials in primary and secondary progressive MS. Brain lesion c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Frontiers in Neurology

سال: 2016

ISSN: 1664-2295

DOI: 10.3389/fneur.2016.00131